Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-3116 plus ripretinib in advanced KIT exon 11-mutant GIST
2024-516476-15-00Phase 2Authorised
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of inlexisertib and ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Deciphera Pharmaceuticals. Primary endpoint: Objective response rate. Planned start Mar 2026; status: authorised.
02
Drugs
inlexisertibripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2024-516476-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516476-15-00.